Actavis Announces OxyContin® Patent Challenge Settlement

           Actavis Announces OxyContin® Patent Challenge Settlement

PR Newswire

PARSIPPANY, N.J., April 26, 2013

PARSIPPANY, N.J., April 26, 2013 /PRNewswire/ --Actavis, Inc. (NYSE: ACT), a
leading specialty pharmaceutical company, today announced that it has entered
into an agreement with Purdue Pharma to settle all outstanding patent
litigation related to Actavis' generic version of the currently marketed
abuse-deterrent formulation of OxyContin^®.

Under the terms of the agreement, Actavis will be licensed to market a
specified number of bottles of its generic OxyContin^® beginning on January 1,
2014. Launch of Actavis' product is contingent upon the Company receiving
final approval from the U.S. Food and Drug Administration (FDA) on its
Abbreviated New Drug Application (ANDA) for generic OxyContin^®.

Alternatively, if Actavis is unable to gain FDA approval of its generic
OxyContin^® prior to September 1, 2014, the Company will be permitted to
launch a specified number of bottles of an authorized generic version of
Purdue's abuse-deterrent product beginning in October 2014.

Actavis anticipates that the agreement will represent more than $100 million
in combined gross profit in 2014 and 2015, more heavily weighted to 2014. The
agreement is expected to result in a more modest contribution from 2016
through 2019. Other terms of the settlement were not disclosed.

"The agreement provides a date certain launch that eliminates the risk of
current and future litigation related to all versions of OxyContin^®," said
Paul Bisaro, President and CEO of Actavis. "It also eliminates the uncertainty
surrounding FDA review and approval of generic versions of abuse deterrent
products. Consumers and Actavis shareholders will now benefit from the
distribution of product beginning in 2014."

OxyContin^® had U.S. sales of approximately $2.8 billion for the twelve month
period ending January 31, 2013 according to IMS Health.

About Actavis, Inc.

Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical
company focused on developing, manufacturing and distributing generic, brand
and biosimilar products. The Company has global and U.S. headquarters in
Parsippany, New Jersey, USA, and international headquarters in Zug,

Actavis is the world's third-largest generics prescription drug manufacturer.
Operating as Actavis Pharma, the Company develops, manufactures and markets
generic, branded generic, legacy brands and Over-the-Counter (OTC) products in
more than 60 countries. The Company is ranked in the top 3 in 12 global
markets, the top 5 in 16 global markets, and in the top 10 in 33 global
markets.  Actavis Pharma also develops and out-licenses generic
pharmaceutical products outside the U.S. through its Medis third-party
business, the world's largest generic pharmaceutical out-licensing business.
Medis has more than 300 customers globally, and offers a broad portfolio of
more than 200 products.

Actavis Specialty Brands is the Company's global branded specialty
pharmaceutical business, which develops and markets a portfolio of
approximately 40 products principally in the United States and Canada that are
focused in the Urology and Women's Health therapeutic categories. Actavis
Specialty Brands is committed to developing and marketing biosimilars products
in Women's Health, Oncology and other therapeutic categories, and currently
has a portfolio of 5 biosimilar products in development. 

Actavis Global Operations has more than 30 manufacturing and distribution
facilities around the world, with a capacity of approximately 44 billion units
annually. Actavis Global Operations also includes Anda, Inc., the
fourth-largest U.S. generic pharmaceutical product distributor in the United

For press release and other company information, visit Actavis' Web site at

Forward-Looking Statement
Statements contained in this press release that refer to non-historical facts
are forward-looking statements that reflect Actavis' current perspective of
existing information as of the date of this release. It is important to note
that Actavis' goals and expectations are not predictions of actual
performance. Actual results may differ materially from Actavis' current
expectations depending upon a number of factors, risks and uncertainties
affecting Actavis' business. These factors include, among others, the
difficulty of predicting the timing or outcome of product development efforts,
including FDA and other regulatory agency approvals and actions, if any; the
impact of competitive products and pricing; the timing and success of product
launches; risks that resolution of patent infringement litigation through
settlement could result in investigations or actions by private parties or
government authorities or agencies; difficulties or delays in manufacturing;
the availability and pricing of third party sourced products and materials;
successful compliance with FDA and other governmental regulations applicable
to Actavis' and its third party manufacturers' facilities, products and/or
businesses; changes in the laws and regulations, including Medicare and
Medicaid, affecting among other things, pricing and reimbursement of
pharmaceutical products; and such other risks and uncertainties detailed in
Actavis' periodic public filings with the Securities and Exchange Commission,
including but not limited to Actavis' Annual Report on Form 10-K for the year
ended December 31, 2012. Except as expressly required by law, Actavis
disclaims any intent or obligation to update these forward-looking statements.

OxyContin® is a trademark of Purdue Pharma L.P.

CONTACTS: Investors:
          Lisa DeFrancesco
          (862) 261-7152
          Charlie Mayr
          (862) 261-8030

(Logo: )

SOURCE Actavis, Inc.

Press spacebar to pause and continue. Press esc to stop.